Ogura H, Tani K, Kozai Y, Watari K, Kodo H, Ozawa K, Asano S, Takaku F
Department of Hematology/Oncology, University of Tokyo.
Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):682-6. doi: 10.1111/j.1349-7006.1990.tb02627.x.
Human interferon-alpha (IFN-alpha) has been shown to be effective in the treatment of Philadelphia chromosome (Ph1)-positive chronic myelogenous leukemia (CML) in the benign stable phase. The present study indicates that IFN-alpha may have a suppressive effect on Ph1-positive clones not only in the early stable phase but also in the accelerated phase with additional chromosomal abnormalities in some patients. In this study, in addition to 5 benign-phase patients, 3 patients with CML in the accelerated phase who had additional chromosomal abnormalities were treated with IFN-alpha. The presence of the Ph1-positive clone was estimated by chromosomal analysis and by Southern analysis at the DNA level using a 3' breakpoint cluster region (bcr) probe. Hematological remission and the suppression of proliferation of Ph1-positive clone to various extents were achieved by IFN-alpha treatment in 2 benign-phase patients and 3 patients with additional chromosomal abnormalities. Interestingly, in one of the latter three patients, Ph1-positive clones with or without additional chromosomal abnormalities were completely suppressed judging from chromosomal analysis and from the disappearance of bcr gene rearrangements.
人α干扰素（IFN-α）已被证明对处于良性稳定期的费城染色体（Ph1）阳性慢性粒细胞白血病（CML）有效。本研究表明，IFN-α不仅在早期稳定期，而且在部分患者伴有额外染色体异常的加速期，可能对Ph1阳性克隆具有抑制作用。在本研究中，除了5例处于良性期的患者外，3例伴有额外染色体异常的加速期CML患者接受了IFN-α治疗。通过染色体分析以及使用3'断裂点簇区域（bcr）探针在DNA水平进行Southern分析来评估Ph1阳性克隆的存在情况。IFN-α治疗使2例良性期患者和3例伴有额外染色体异常的患者实现了血液学缓解，并在不同程度上抑制了Ph1阳性克隆的增殖。有趣的是，在后3例患者中的1例中，从染色体分析以及bcr基因重排的消失情况判断，伴有或不伴有额外染色体异常的Ph1阳性克隆均被完全抑制。
